DFE Pharma’s broad excipient portfolio includes starch, lactose and microcrystaline cellulose, with applications as, for example, inhalants and superdisintegrants. The company both manufactures excipients and partners with pharma companies to improve their product performance.
Corporate Head Office
DFE Pharma GmbH & Co KG
Klever Strasse 187
Phone / ContactT: +49 2823 928 877 0
F: +49 2823 928 877 99
E: [email protected]
DFE Pharma is a major global provider of excipients and excipient expertise. Its portfolio includes starch, lactose, microcrystalline cellulose (MCC), inhalants and superdisintegrants.
The company has production locations in the Netherlands, Germany, New Zealand and India, and sales offices in Germany, the US, Singapore, Japan, India, Brazil and China, and employs 360 people.
The DFE Pharma brand was formed in 2020 by the combination of DMV-Fonterra Excipients and DOMO-pharma. The company traces it roots back to 1900, to dairy producers in both the Netherlands and New Zealand. It is jointly owned by Royal FrieslandCampina, one of the world’s largest multinational dairy companies, and CVC Capital Partners, a leading global investor that acquired a 50% share.